

Product datasheet for TL316476V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Caspase 2 (CASP2) Human shRNA Lentiviral Particle (Locus ID 835)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: Caspase 2 (CASP2) Human shRNA Lentiviral Particle (Locus ID 835)

Locus ID: 835

Synonyms: CASP-2; ICH1; NEDD-2; NEDD2; PPP1R57

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: CASP2 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001224, NM 032982, NM 032983, NM 032984, NM 032982.1, NM 032982.2,

NM 032982.3, NM 032983.1, NM 032983.2, NM 032983.3, NM 001224.1, NM 001224.2,

NM 001224.3, NM 001224.4, NM 032984.2, BC002427, BC002427.2, BM998653,

NM 032983.4, NM 032982.4

UniProt ID: P42575

Summary: This gene encodes a member of the cysteine-aspartic acid protease (caspase) family.

Caspases mediate cellular apoptosis through the proteolytic cleavage of specific protein substrates. The encoded protein may function in stress-induced cell death pathways, cell cycle maintenance, and the suppression of tumorigenesis. Increased expression of this gene may play a role in neurodegenerative disorders including Alzheimer's disease, Huntington's disease and temporal lobe epilepsy. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. [provided by RefSeq, Jan 2011]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).